Notably, neither CD4+ nor CD8+ T‐cells exhibited an increase, further supporting that the reduction in tumor burden was driven by the MDCa@RBC‐Alipo‐induced innate antitumor immunity (Figure S16, Supporting Information). The gene discussed is CD4; the disease is neoplasm.